HOME
SEARCH
RSS FEED
SUBSCRIBE
A Method to Expand a Population of Regulatory T Cells Optimal for the Treatment of Autoimmune Diseases
Case ID:
TAB-2481
Web Published:
12/6/2022
Description:
The transfusion of regulatory T cells (Tregs) has been used in the clinic to successfully prevent graft vs. host disease and is currently being evaluated in the treatment of other autoimmune diseases, such as organ graft rejection, type 1 diabetes and multiple sclerosis. Prior to transfusion, adoptive regulatory T cell transfer requires the expansion of regulatory T cells in culture; this results in a mixed population of regulatory T cells that limits the effectiveness of the transferred cells.
Scientists at the NIH have developed a method that promotes the expansion of regulatory T cells that are longer lived, more stable, and more suppressive of the autoimmune response. By supplementing T cell cultures with DNA oligonucleotides, the inventors were able to enrich the regulatory T cell population that enhanced the suppression of the autoimmune response. This method has the potential to more effectively generate regulatory T cells for the treatment of autoimmune diseases.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
Direct Link:
https://nih.technologypublisher.com/tech/A_Method_to_Expand_a_Population_of_R egulatory_T_Cells_Optimal_for_the_Treatment_of_Autoimmune_Diseases
Category(s):
Licensing
Diagnostics
Research Materials
Therapeutics
Bookmark this page
Download as PDF
For Information, Contact:
Yogikala Prabhu
Technology Transfer Patent Specialist
NIH Technology Transfer
+1 240 276 5530
yogikala.prabhu@nih.gov
Inventors:
Ethan Shevach
Yong Chan Kim
Keywords:
Cells
FOXP3+
Helios-expressing
Human
IBXXXX
IDXXXX
IXXXXX
oligonucleotides
Random-sequenced
Regulatory
Stabilization
T
Usingrandom-sequenced
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum